Key result
Human iPS-derived bioengineered cardiac tissue with the LMNA p.R225X mutation exhibited significantly impaired contractile force (0.56 mN vs 1.10 mN, P=0.001) compared to wild-type control tissue.
Absolute Event Rate: 0.56% vs 1.1%
p-value: p=0.001
Human iPS-derived bioengineered cardiac tissue with the LMNA p.R225X mutation demonstrates impaired systolic function and downregulated expression of contractile and calcium-handling genes, serving as a promising in vitro model for dilated cardiomyopathy.
Does not alter clinical management of LMNA cardiomyopathy; leaves open iPS-derived models for mechanistic DCM research.
Dilated cardiomyopathy (DCM) is caused by various gene variants and characterized by systolic dysfunction. Lamin variants have been reported to have a poor prognosis. Medical and device therapies are not sufficient to improve the prognosis of DCM with the lamin variants. Recently, induced pluripotent stem (iPS) cells have been used for research on genetic disorders. However, few studies have evaluated the contractile function of cardiac tissue with lamin variants. The aim of this study was to elucidate the function of cardiac cell sheet tissue derived from patients with lamin variant DCM. iPS cells were generated from a patient with lamin A/C (LMNA) -mutant DCM (LMNA p.R225X mutation). After cardiac differentiation and purification, cardiac cell sheets that were fabricated through cultivation on a temperature-responsive culture dish were transferred to the surface of the fibrin gel, and the contractile force was measured. The contractile force and maximum contraction velocity, but not the maximum relaxation velocity, were significantly decreased in cardiac cell sheet tissue with the lamin variant. A qRT-PCR analysis revealed that mRNA expression of some contractile proteins, cardiac transcription factors, Ca2+-handling genes, and ion channels were downregulated in cardiac tissue with the lamin variant.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2022) studied Dilated cardiomyopathy (Lamin variant). LMNA p.R225X mutation vs. Wild-type iPS cells (201B7) was evaluated on Contractile force (mN) (p=0.001). Human iPS-derived bioengineered cardiac tissue with the LMNA p.R225X mutation exhibited significantly impaired contractile force (0.56 mN vs 1.10 mN, P=0.001) compared to wild-type control tissue.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: